九芝堂(000989.SZ):全資子公司研發新藥YB211啟動臨牀試驗
格隆匯12月13日丨九芝堂(000989.SZ)公佈,2023年12月13日,九芝堂股份有限公司全資子公司牡丹江友搏藥業有限責任公司(簡稱“友搏藥業”)與復旦大學附屬華山醫院、康龍化成(成都)臨牀研究服務有限公司(臨牀CRO公司)召開了關於開展“評價中國健康成人受試者單次和多次靜脈注射YB211的耐受性、安全性和藥代動力學特徵的單中心、隨機、盲法、對照設計的I期臨牀試驗”的臨牀試驗啟動會。
YB211項目是具有全新化學結構的環脂肽類1類化藥新藥,其化合物、製備方法等核心技術均已獲得國際和國內發明專利授權與全球獨家許可。本藥品申請適應症為對本品敏感的革蘭氏陽性病原菌所致的複雜性皮膚及軟組織感染(cSSTI),其研發旨在提高環脂肽類抗菌藥物的安全性與有效性,為臨牀提供一種新的選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.